286 related articles for article (PubMed ID: 17827142)
1. Costs associated with shorter duration of antibiotic therapy in hospitalized patients with mild-to-moderate severe community-acquired pneumonia.
Opmeer BC; El Moussaoui R; Bossuyt PM; Speelman P; Prins JM; de Borgie CA
J Antimicrob Chemother; 2007 Nov; 60(5):1131-6. PubMed ID: 17827142
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of exclusively oral antibiotic therapy in patients hospitalized with nonsevere community-acquired pneumonia: a retrospective study and meta-analysis.
Marras TK; Nopmaneejumruslers C; Chan CK
Am J Med; 2004 Mar; 116(6):385-93. PubMed ID: 15006587
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of the cost-effectiveness relationship in the empirical treatment in patients with infections of the lower respiratory tract acquired in the community].
Bertrán MJ; Trilla A; Codina C; Carné X; Ribas J; Asenjo MA
Enferm Infecc Microbiol Clin; 2000 Nov; 18(9):445-51. PubMed ID: 11149168
[TBL] [Abstract][Full Text] [Related]
4. A comparison of levofloxacin and moxifloxacin use in hospitalized community-acquired pneumonia (CAP) patients in the US: focus on length of stay.
Schein J; Janagap-Benson C; Grant R; Sikirica V; Doshi D; Olson W
Curr Med Res Opin; 2008 Mar; 24(3):895-906. PubMed ID: 18419876
[TBL] [Abstract][Full Text] [Related]
5. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia.
Houck PM; Bratzler DW; Nsa W; Ma A; Bartlett JG
Arch Intern Med; 2004 Mar; 164(6):637-44. PubMed ID: 15037492
[TBL] [Abstract][Full Text] [Related]
6. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
7. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study.
File TM; Mandell LA; Tillotson G; Kostov K; Georgiev O
J Antimicrob Chemother; 2007 Jul; 60(1):112-20. PubMed ID: 17537866
[TBL] [Abstract][Full Text] [Related]
8. Prospective, randomised study to compare empirical treatment versus targeted treatment on the basis of the urine antigen results in hospitalised patients with community-acquired pneumonia.
Falguera M; Ruiz-González A; Schoenenberger JA; Touzón C; Gázquez I; Galindo C; Porcel JM
Thorax; 2010 Feb; 65(2):101-6. PubMed ID: 19703825
[TBL] [Abstract][Full Text] [Related]
9. [A pharmacoeconomic study of in-hospital treatment against community-acquired pneumonia].
Bermejo Vicedo T; Torralba Arranz A; Hidalgo Correas FJ; Millán Santos I; Rodríguez Morradan B
Farm Hosp; 2004; 28(1):29-35. PubMed ID: 15012176
[TBL] [Abstract][Full Text] [Related]
10. Treatment costs associated with community-acquired pneumonia by community level of antimicrobial resistance.
Asche C; McAdam-Marx C; Seal B; Crookston B; Mullins CD
J Antimicrob Chemother; 2008 May; 61(5):1162-8. PubMed ID: 18310136
[TBL] [Abstract][Full Text] [Related]
11. [Socioeconomic evaluation of the effect of rhDNase on the cost of treating infections of the respiratory tract in patients with cystic fibrosis].
von der Schulenburg JM; Greiner W; von der Hardt H
Med Klin (Munich); 1995 Apr; 90(4):220-4. PubMed ID: 7776934
[TBL] [Abstract][Full Text] [Related]
12. How long should we treat community-acquired pneumonia?
Scalera NM; File TM
Curr Opin Infect Dis; 2007 Apr; 20(2):177-81. PubMed ID: 17496577
[TBL] [Abstract][Full Text] [Related]
13. Economic cost of community-acquired pneumonia in New Zealand adults.
Scott G; Scott H; Turley M; Baker M
N Z Med J; 2004 Jun; 117(1196):U933. PubMed ID: 15280937
[TBL] [Abstract][Full Text] [Related]
14. Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia.
Stone RA; Mor MK; Lave JR; Hough LJ; Fine MJ
Am J Manag Care; 2005 Aug; 11(8):491-9. PubMed ID: 16095435
[TBL] [Abstract][Full Text] [Related]
15. Management of community-acquired pneumonia by trained family general practitioners.
Potena A; Simoni M; Cellini M; Cartabellotta A; Ballerin L; Piattella M; Putinati S
Int J Tuberc Lung Dis; 2008 Jan; 12(1):19-25. PubMed ID: 18173872
[TBL] [Abstract][Full Text] [Related]
16. Modified guidelines impact on antibiotic use and costs: duration of treatment for pneumonia in a neurosurgical ICU is reduced.
Meyer E; Buttler J; Schneider C; Strehl E; Schroeren-Boersch B; Gastmeier P; Ruden H; Zentner J; Daschner FD; Schwab F
J Antimicrob Chemother; 2007 Jun; 59(6):1148-54. PubMed ID: 17434880
[TBL] [Abstract][Full Text] [Related]
17. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors.
Schouten JA; Hulscher ME; Kullberg BJ; Cox A; Gyssens IC; van der Meer JW; Grol RP
J Antimicrob Chemother; 2005 Sep; 56(3):575-82. PubMed ID: 16049096
[TBL] [Abstract][Full Text] [Related]
18. Costs of treating lower respiratory tract infections.
Monte SV; Paolini NM; Slazak EM; Schentag JJ; Paladino JA
Am J Manag Care; 2008 Apr; 14(4):190-6. PubMed ID: 18402511
[TBL] [Abstract][Full Text] [Related]
19. Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumonia.
File TM; Milkovich G; Tennenberg AM; Xiang JX; Khashab MM; Zadeikis N
Curr Med Res Opin; 2004 Sep; 20(9):1473-81. PubMed ID: 15383197
[TBL] [Abstract][Full Text] [Related]
20. In-hospital observation after antibiotic switch in pneumonia: a national evaluation.
Nathan RV; Rhew DC; Murray C; Bratzler DW; Houck PM; Weingarten SR
Am J Med; 2006 Jun; 119(6):512.e1-7. PubMed ID: 16750965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
